CN106178006A - 医用碘‑131碳微球及其制备方法 - Google Patents
医用碘‑131碳微球及其制备方法 Download PDFInfo
- Publication number
- CN106178006A CN106178006A CN201610655270.5A CN201610655270A CN106178006A CN 106178006 A CN106178006 A CN 106178006A CN 201610655270 A CN201610655270 A CN 201610655270A CN 106178006 A CN106178006 A CN 106178006A
- Authority
- CN
- China
- Prior art keywords
- carbosphere
- medical
- iodine
- solution
- medical iodine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 title claims abstract description 86
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 27
- 238000003745 diagnosis Methods 0.000 claims abstract description 14
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000001959 radiotherapy Methods 0.000 claims abstract description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000010521 absorption reaction Methods 0.000 claims abstract description 10
- 239000007800 oxidant agent Substances 0.000 claims abstract description 10
- 230000004807 localization Effects 0.000 claims abstract description 9
- 238000001727 in vivo Methods 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims description 39
- 150000002500 ions Chemical class 0.000 claims description 36
- 238000000926 separation method Methods 0.000 claims description 34
- 239000004005 microsphere Substances 0.000 claims description 23
- 238000001556 precipitation Methods 0.000 claims description 23
- 239000011734 sodium Substances 0.000 claims description 23
- 238000002791 soaking Methods 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- 229910021607 Silver chloride Inorganic materials 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims description 11
- 238000001179 sorption measurement Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000012535 impurity Substances 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 239000011630 iodine Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 230000001590 oxidative effect Effects 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229910017604 nitric acid Inorganic materials 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 101710134784 Agnoprotein Proteins 0.000 claims description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 4
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 230000009514 concussion Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000011368 organic material Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 238000005554 pickling Methods 0.000 claims description 2
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims description 2
- 239000001230 potassium iodate Substances 0.000 claims description 2
- 229940093930 potassium iodate Drugs 0.000 claims description 2
- 235000006666 potassium iodate Nutrition 0.000 claims description 2
- 239000012286 potassium permanganate Substances 0.000 claims description 2
- 239000012798 spherical particle Substances 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 48
- 238000001914 filtration Methods 0.000 description 14
- 239000011521 glass Substances 0.000 description 12
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 12
- 229940006461 iodide ion Drugs 0.000 description 12
- 229910021612 Silver iodide Inorganic materials 0.000 description 10
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(I) nitrate Inorganic materials [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 10
- 238000007711 solidification Methods 0.000 description 8
- 230000008023 solidification Effects 0.000 description 8
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229940045105 silver iodide Drugs 0.000 description 6
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 5
- 239000011805 ball Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 229940097886 phosphorus 32 Drugs 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 208000005189 Embolism Diseases 0.000 description 3
- 208000001435 Thromboembolism Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002555 ionophore Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910001868 water Inorganic materials 0.000 description 3
- 206010010254 Concussion Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000000236 ionophoric effect Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011806 microball Substances 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- CIOAGBVUUVVLOB-NJFSPNSNSA-N Strontium-90 Chemical compound [90Sr] CIOAGBVUUVVLOB-NJFSPNSNSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043966 Tongue neoplasm malignant stage unspecified Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000006288 Vascular Tissue Neoplasms Diseases 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- 208000029185 blood vessel neoplasm Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000003575 carbonaceous material Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000009388 chemical precipitation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000010110 radioembolization Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
- A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1268—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B7/00—Halogens; Halogen acids
- C01B7/13—Iodine; Hydrogen iodide
- C01B7/14—Iodine
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/62—Submicrometer sized, i.e. from 0.1-1 micrometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/80—Particles consisting of a mixture of two or more inorganic phases
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/80—Compositional purity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (27)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610655270.5A CN106178006B (zh) | 2016-08-11 | 2016-08-11 | 医用碘-131碳微球及其制备方法 |
PCT/CN2017/096890 WO2018028642A1 (zh) | 2016-08-11 | 2017-08-10 | 医用碘-131碳微球及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610655270.5A CN106178006B (zh) | 2016-08-11 | 2016-08-11 | 医用碘-131碳微球及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106178006A true CN106178006A (zh) | 2016-12-07 |
CN106178006B CN106178006B (zh) | 2019-09-03 |
Family
ID=57515021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610655270.5A Active CN106178006B (zh) | 2016-08-11 | 2016-08-11 | 医用碘-131碳微球及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN106178006B (zh) |
WO (1) | WO2018028642A1 (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018028642A1 (zh) * | 2016-08-11 | 2018-02-15 | 成都纽瑞特医疗科技有限公司 | 医用碘-131碳微球及其制备方法 |
CN109580307A (zh) * | 2018-12-17 | 2019-04-05 | 中国原子能科学研究院 | 一种i-131标准奶粉样品的制备方法 |
CN110342927A (zh) * | 2019-07-04 | 2019-10-18 | 中国科学院近代物理研究所 | 医用90Y-ZrO2陶瓷微球及其制备方法 |
CN111920965A (zh) * | 2019-05-13 | 2020-11-13 | 深圳市大西塔科技有限公司 | 放射性颗粒及其制备方法和应用 |
CN111920966A (zh) * | 2019-05-13 | 2020-11-13 | 深圳市大西塔科技有限公司 | 放射性颗粒及其制备方法和应用 |
CN112843260A (zh) * | 2021-02-02 | 2021-05-28 | 苏州大学 | 一种医用放射性二氧化硅微球及其制备方法与应用 |
CN115569634A (zh) * | 2022-10-27 | 2023-01-06 | 中盐常州化工股份有限公司 | 一种离子膜烧碱制备用除碘碳吸附材料及其制备方法 |
CN115607694A (zh) * | 2022-12-13 | 2023-01-17 | 北京普尔伟业生物科技有限公司 | 一种放射性碳微球及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070253898A1 (en) * | 2000-10-25 | 2007-11-01 | Sirtex Medical Limited | Polymer based radionuclide containing particulate material |
CN102671220A (zh) * | 2011-03-11 | 2012-09-19 | 成都云克药业有限责任公司 | 一种放射性阴离子树脂微球及其制备方法 |
CN104401969A (zh) * | 2015-01-08 | 2015-03-11 | 北京化工大学 | 一种常压干燥制备石墨烯微球的方法 |
CN105457493A (zh) * | 2014-09-10 | 2016-04-06 | 中国辐射防护研究院 | 一种同位素交换法制备放射性单质碘的方法及系统 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103688996B (zh) * | 2013-11-28 | 2014-12-10 | 太原理工大学 | 一种用废旧棉纤维制备载银抗菌剂的方法 |
CN106178006B (zh) * | 2016-08-11 | 2019-09-03 | 成都纽瑞特医疗科技有限公司 | 医用碘-131碳微球及其制备方法 |
-
2016
- 2016-08-11 CN CN201610655270.5A patent/CN106178006B/zh active Active
-
2017
- 2017-08-10 WO PCT/CN2017/096890 patent/WO2018028642A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070253898A1 (en) * | 2000-10-25 | 2007-11-01 | Sirtex Medical Limited | Polymer based radionuclide containing particulate material |
CN102671220A (zh) * | 2011-03-11 | 2012-09-19 | 成都云克药业有限责任公司 | 一种放射性阴离子树脂微球及其制备方法 |
CN105457493A (zh) * | 2014-09-10 | 2016-04-06 | 中国辐射防护研究院 | 一种同位素交换法制备放射性单质碘的方法及系统 |
CN104401969A (zh) * | 2015-01-08 | 2015-03-11 | 北京化工大学 | 一种常压干燥制备石墨烯微球的方法 |
Non-Patent Citations (2)
Title |
---|
ZHIQING LIN ET AL: "Biodistribution of single-walled carbon nanotubes in rats", 《TOXICOL. RES.》 * |
李明起 等: "医用放射性核素生产现状和主要问题", 《同位素》 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018028642A1 (zh) * | 2016-08-11 | 2018-02-15 | 成都纽瑞特医疗科技有限公司 | 医用碘-131碳微球及其制备方法 |
CN109580307A (zh) * | 2018-12-17 | 2019-04-05 | 中国原子能科学研究院 | 一种i-131标准奶粉样品的制备方法 |
CN111920965A (zh) * | 2019-05-13 | 2020-11-13 | 深圳市大西塔科技有限公司 | 放射性颗粒及其制备方法和应用 |
CN111920966A (zh) * | 2019-05-13 | 2020-11-13 | 深圳市大西塔科技有限公司 | 放射性颗粒及其制备方法和应用 |
WO2020228559A1 (zh) * | 2019-05-13 | 2020-11-19 | 深圳市大西塔科技有限公司 | 放射性颗粒及其制备方法和应用 |
WO2020228558A1 (zh) * | 2019-05-13 | 2020-11-19 | 深圳市大西塔科技有限公司 | 放射性颗粒及其制备方法和应用 |
CN110342927A (zh) * | 2019-07-04 | 2019-10-18 | 中国科学院近代物理研究所 | 医用90Y-ZrO2陶瓷微球及其制备方法 |
CN112843260A (zh) * | 2021-02-02 | 2021-05-28 | 苏州大学 | 一种医用放射性二氧化硅微球及其制备方法与应用 |
CN115569634A (zh) * | 2022-10-27 | 2023-01-06 | 中盐常州化工股份有限公司 | 一种离子膜烧碱制备用除碘碳吸附材料及其制备方法 |
CN115607694A (zh) * | 2022-12-13 | 2023-01-17 | 北京普尔伟业生物科技有限公司 | 一种放射性碳微球及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106178006B (zh) | 2019-09-03 |
WO2018028642A1 (zh) | 2018-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106178006A (zh) | 医用碘‑131碳微球及其制备方法 | |
CN1194764C (zh) | 镭-223在制备用于治疗影响骨的疾病的药物中的用途 | |
CN107715122B (zh) | 医用磷酸钇[90y32po4]碳微球及其制备方法 | |
JP5969462B2 (ja) | 医薬許容純度の223Ra試薬の製造方法 | |
US10940219B2 (en) | Radioactive microspheres made of nanoporous glass for radiation therapy | |
TWI675669B (zh) | 放射微球及其製備方法 | |
JP2003529517A (ja) | 放射線照射ウラン溶液からモリブデン−99を抽出する無機吸着剤、およびその使用方法 | |
CN107715123B (zh) | 医用磷-32碳微球及其制备方法 | |
Amor-Coarasa et al. | Lyophilized Kit for the Preparation of the PET Perfusion Agent [68Ga]‐MAA | |
NO154296B (no) | Fremgangsmaate og radioisotopgenerator for fremstilling av en ikke-toksisk, farmasoeytisk akseptabel 195m au-holdig vaeske. | |
CN112843260B (zh) | 一种医用放射性二氧化硅微球及其制备方法与应用 | |
CN107715124B (zh) | 医用钇-90碳微球及其制备方法 | |
CN109529096A (zh) | 一种均匀粒径明胶栓塞剂及其制备方法 | |
TW201726179A (zh) | 純化方法 | |
CN111603576B (zh) | 一种锝[99mTc]炭微球注射液及其制备方法和用途 | |
RU2695635C1 (ru) | Способ получения радионуклеида лютеций-177 | |
CN110639033B (zh) | 一种基于液态金属的可视化放射微球及其制备方法 | |
JP5956533B2 (ja) | 放射ターゲット薬物調製用キット及び放射ターゲット薬物の調製方法及び用途 | |
RU2463075C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ МЕЧЕННОГО ТЕХНЕЦИЕМ-99m НАНОКОЛЛОИДА | |
RU2485059C1 (ru) | Способ получения микросфер для радиотерапии | |
JP6901498B2 (ja) | 同位体調製方法 | |
El-Tawoosy et al. | Radioiodination and biological evaluation of salbutamol as a β 2-adrenoceptor agonist | |
He et al. | Precision interventional brachytherapy: A promising strategy toward treatment of malignant tumors | |
RU2418606C1 (ru) | Способ получения радиофармпрепарата с палладием-103 | |
IL34751A (en) | Production of fission product technetium 99-m generator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170421 Address after: 610041 Chengdu province high tech Zone, the South Ring Road, No. three, No. 28, building No. 17, No. 13 Applicant after: Li Maoliang Applicant after: Li Yiran Applicant after: Qian Jihui Applicant after: Cai Jiming Applicant after: Cai Shurui Address before: 610041 Chengdu province high tech Zone, the South Ring Road, No. three, No. 28, building No. 17, No. 13 Applicant before: Li Shuhui Applicant before: Qian Jihui Applicant before: Suo Mingxiang |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180816 Address after: 610200 Chengdu, Sichuan, Shuangliu District, West Hang Kong Economic Development Zone Airport three Road 999. Applicant after: CHENGDU NEW RADIOMEDICINE TECHNOLOGY Co.,Ltd. Address before: 610041 No. 17, No. 28, South three section of the first ring road, Chengdu High-tech Zone, Sichuan, China No. 13 Applicant before: Li Maoliang Applicant before: Li Yiran Applicant before: Qian Jihui Applicant before: Cai Jiming Applicant before: Cai Shurui |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 610200 Chengdu, Sichuan, Shuangliu District, West Hang Kong Economic Development Zone Airport three Road 999. Patentee after: Chengdu nurit Medical Technology Co.,Ltd. Address before: 610200 Chengdu, Sichuan, Shuangliu District, West Hang Kong Economic Development Zone Airport three Road 999. Patentee before: CHENGDU NEW RADIOMEDICINE TECHNOLOGY Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medical iodine-131 carbon microsphere and its preparation method Effective date of registration: 20200923 Granted publication date: 20190903 Pledgee: Chengdu SME financing Company Limited by Guarantee Pledgor: Chengdu nurit Medical Technology Co.,Ltd. Registration number: Y2020980006381 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221026 Granted publication date: 20190903 Pledgee: Chengdu SME financing Company Limited by Guarantee Pledgor: Chengdu nurit Medical Technology Co.,Ltd. Registration number: Y2020980006381 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |